XOMA Quote, Financials, Valuation and Earnings

Palatin Technologies has a net margin of 52.48% compared to XOMA Royalty Corp.'s net margin of --. XOMA Royalty Corp.'s return on equity of 17.31% beat Palatin Technologies's return on equity of --.

XOMA Royalty Corp. has a consensus price target of $70.67, signalling upside risk potential of 127.01%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than XOMA Royalty Corp., analysts believe Palatin Technologies is more attractive than XOMA Royalty Corp..

XOMA Royalty Corp. has a beta of 0.941, which suggesting that the stock is 5.919% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

XOMA Royalty Corp. has a quarterly dividend of $0.54 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. XOMA Royalty Corp. pays 39.59% of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend. XOMA Royalty Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

XOMA Royalty Corp. quarterly revenues are $9.4M, which are larger than Palatin Technologies quarterly revenues of --. XOMA Royalty Corp.'s net income of $10.3M is higher than Palatin Technologies's net income of --. Notably, XOMA Royalty Corp.'s price-to-earnings ratio is 41.76x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for XOMA Royalty Corp. is 10.83x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Tango Therapeutics, Inc. has a net margin of 52.48% compared to XOMA Royalty Corp.'s net margin of 29.52%. XOMA Royalty Corp.'s return on equity of 17.31% beat Tango Therapeutics, Inc.'s return on equity of -56.44%.

XOMA Royalty Corp. has a consensus price target of $70.67, signalling upside risk potential of 127.01%. On the other hand Tango Therapeutics, Inc. has an analysts' consensus of $13.25 which suggests that it could grow by 33.84%. Given that XOMA Royalty Corp. has higher upside potential than Tango Therapeutics, Inc., analysts believe XOMA Royalty Corp. is more attractive than Tango Therapeutics, Inc..

XOMA Royalty Corp. has a beta of 0.941, which suggesting that the stock is 5.919% less volatile than S&P 500. In comparison Tango Therapeutics, Inc. has a beta of 1.718, suggesting its more volatile than the S&P 500 by 71.771%.

XOMA Royalty Corp. has a quarterly dividend of $0.54 per share corresponding to a yield of 0%. Tango Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. XOMA Royalty Corp. pays 39.59% of its earnings as a dividend. Tango Therapeutics, Inc. pays out -- of its earnings as a dividend. XOMA Royalty Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

XOMA Royalty Corp. quarterly revenues are $9.4M, which are smaller than Tango Therapeutics, Inc. quarterly revenues of $53.8M. XOMA Royalty Corp.'s net income of $10.3M is lower than Tango Therapeutics, Inc.'s net income of $15.9M. Notably, XOMA Royalty Corp.'s price-to-earnings ratio is 41.76x while Tango Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for XOMA Royalty Corp. is 10.83x versus 16.39x for Tango Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vistagen Therapeutics, Inc. has a net margin of 52.48% compared to XOMA Royalty Corp.'s net margin of -7525.97%. XOMA Royalty Corp.'s return on equity of 17.31% beat Vistagen Therapeutics, Inc.'s return on equity of -76.57%.

XOMA Royalty Corp. has a consensus price target of $70.67, signalling upside risk potential of 127.01%. On the other hand Vistagen Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 238.79%. Given that Vistagen Therapeutics, Inc. has higher upside potential than XOMA Royalty Corp., analysts believe Vistagen Therapeutics, Inc. is more attractive than XOMA Royalty Corp..

XOMA Royalty Corp. has a beta of 0.941, which suggesting that the stock is 5.919% less volatile than S&P 500. In comparison Vistagen Therapeutics, Inc. has a beta of 0.561, suggesting its less volatile than the S&P 500 by 43.86%.

XOMA Royalty Corp. has a quarterly dividend of $0.54 per share corresponding to a yield of 0%. Vistagen Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. XOMA Royalty Corp. pays 39.59% of its earnings as a dividend. Vistagen Therapeutics, Inc. pays out -- of its earnings as a dividend. XOMA Royalty Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

XOMA Royalty Corp. quarterly revenues are $9.4M, which are larger than Vistagen Therapeutics, Inc. quarterly revenues of $258K. XOMA Royalty Corp.'s net income of $10.3M is higher than Vistagen Therapeutics, Inc.'s net income of -$19.4M. Notably, XOMA Royalty Corp.'s price-to-earnings ratio is 41.76x while Vistagen Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for XOMA Royalty Corp. is 10.83x versus 150.22x for Vistagen Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Zevra Therapeutics, Inc. has a net margin of 52.48% compared to XOMA Royalty Corp.'s net margin of -2.09%. XOMA Royalty Corp.'s return on equity of 17.31% beat Zevra Therapeutics, Inc.'s return on equity of 44.06%.

XOMA Royalty Corp. has a consensus price target of $70.67, signalling upside risk potential of 127.01%. On the other hand Zevra Therapeutics, Inc. has an analysts' consensus of $23.10 which suggests that it could grow by 160.31%. Given that Zevra Therapeutics, Inc. has higher upside potential than XOMA Royalty Corp., analysts believe Zevra Therapeutics, Inc. is more attractive than XOMA Royalty Corp..

XOMA Royalty Corp. has a beta of 0.941, which suggesting that the stock is 5.919% less volatile than S&P 500. In comparison Zevra Therapeutics, Inc. has a beta of 1.009, suggesting its more volatile than the S&P 500 by 0.92699999999999%.

XOMA Royalty Corp. has a quarterly dividend of $0.54 per share corresponding to a yield of 0%. Zevra Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. XOMA Royalty Corp. pays 39.59% of its earnings as a dividend. Zevra Therapeutics, Inc. pays out -- of its earnings as a dividend. XOMA Royalty Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

XOMA Royalty Corp. quarterly revenues are $9.4M, which are smaller than Zevra Therapeutics, Inc. quarterly revenues of $26.1M. XOMA Royalty Corp.'s net income of $10.3M is higher than Zevra Therapeutics, Inc.'s net income of -$544K. Notably, XOMA Royalty Corp.'s price-to-earnings ratio is 41.76x while Zevra Therapeutics, Inc.'s PE ratio is 13.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for XOMA Royalty Corp. is 10.83x versus 5.61x for Zevra Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.